Pharmagen, Inc. announced that effective June 1, 2014, it has appointed three additional members to its Board of Directors, which now consists of five members. Under its agreement with Bagel Boy Equity Group II, LLC, and as part of its Consolidation and Capital Restructure Plan, the company agreed to establish a five member Board of Directors in order to create a more transparent and mutually aligned organization between the founders, new investment, and targets that are part of the Company's Roll-up Consolidation Plan. The newly created five member Board of Directors is comprised of the following individuals: Mackie Barch, CEO, Pharmagen, Inc.; Richard A. Wolpow, (Chairman) Managing Partner, Bagel Boy Equity Group II LLC; Danny Barnes, PharmD, President & CEO, Triangle Compounding Pharmacy; Stephen M. Perry, President & CEO Kymanox, LLC; and David S. Rowley, Managing Partner, Chestnut Hill Partners.